| Bioactivity | EPZ028862 is a selective SMYD3 inhibitor for cancer research[1]. |
| In Vivo | The pharmacokinetic parameters of EPZ028862( IV: 1 mg/kg; PO: 5 mg/kg) Parameter |
| Name | EPZ028862 |
| CAS | 1887082-53-2 |
| Formula | C20H30N4O4S |
| Molar Mass | 422.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Michael J Thomenius, et al. Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLoS One. 2018 Jun 1;13(6):e0197372. |